STAT-Diagnostica & Innovation (STAT-Dx) is a Spanish start-up based in Barcelona developing a new molecular diagnostics device, capable of identifying a wide range of infectious pathogens, such as meningitis, respiratory or gastro-intestinal infections in approximately one hour.
The European Investment Bank (EIB) is supporting the improvement of infectious diseases diagnostics by STAT-Dx, through the provision of a €20m loan to STAT-Dx. The technology enables clinicians to test simultaneously for the presence or absence of multiple pathogens caused by or associated with specific syndromes, allowing faster diagnostics and improving survival rates in ‘near-to-care’ environments, such as intensive care units and emergency rooms.
The DiagCORE system developed by STAT-Dx is a cartridge based single-test solution. The company says that by providing instantly available results, this new technology will enable immediate and well informed medical decisions to be made.
Carlos Moedas, Commissioner for Research, Science and Innovation said: "This loan is an example of how the European Commission employs innovative financing mechanisms to support the fight against major threats to society, such as antimicrobial resistance. With this project, a quick diagnosis will enable better clinical decision-making and targeted patient management, and speed up the development of an innovative diagnostics platform for infectious diseases.
Innovation and skills are key ingredients for ensuring sustainable growth and creating high-value jobs. EIB is a major partner for projects that develop innovation and long-term competitiveness for a growing economy. In 2016, the EIB supported innovation and skills with €13.5 billion of financing.
The InnovFin EU research programme was launched in 2014 and is designed to facilitate access to finance for innovative business.
Ambroise Fayolle, EIB Vice-President, said: ”Innovation and research is a priority of the EU bank. The agreement signed today with the company STAT-Dx illustrates the EIB's determination to back high risk projects that have a direct positive impact on the lives of citizens benefiting from the most outstanding technology made in Europe."
The programme which runs until 2020 will offer small and large companies and the promoters of research infrastructure a range of tailored products, which will provide more than €15 bn of financial support for research and innovation (R&I).
For more information visit: www.stat-dx.com
